Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Receives $1.35 Average PT from Analysts

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have been assigned an average recommendation of “Reduce” from the eight brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $1.3517.

A number of analysts have recently weighed in on ADAP shares. HC Wainwright reaffirmed a “neutral” rating on shares of Adaptimmune Therapeutics in a research report on Tuesday, July 29th. Guggenheim lowered Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 29th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, October 8th.

Adaptimmune Therapeutics Stock Down 10.5%

NASDAQ:ADAP opened at $0.06 on Friday. The stock’s fifty day moving average is $0.10 and its two-hundred day moving average is $0.18. Adaptimmune Therapeutics has a 52 week low of $0.04 and a 52 week high of $0.86. The stock has a market capitalization of $15.35 million, a price-to-earnings ratio of -0.09 and a beta of 2.49.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 163.73% and a negative net margin of 260.82%.The company had revenue of $13.68 million for the quarter, compared to analysts’ expectations of $11.04 million. On average, sell-side analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Insider Buying and Selling at Adaptimmune Therapeutics

In other news, Director Ali Behbahani sold 14,671,794 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $0.01, for a total transaction of $146,717.94. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 19,803,000 shares of company stock worth $198,030 over the last 90 days. 12.44% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several large investors have recently bought and sold shares of the business. B. Riley Wealth Advisors Inc. purchased a new position in Adaptimmune Therapeutics in the third quarter valued at $65,000. Empirical Finance LLC purchased a new position in Adaptimmune Therapeutics in the second quarter valued at $192,000. Acadian Asset Management LLC increased its holdings in Adaptimmune Therapeutics by 334.8% in the first quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company’s stock valued at $424,000 after buying an additional 1,707,999 shares during the last quarter. Two Seas Capital LP increased its holdings in Adaptimmune Therapeutics by 10.0% in the second quarter. Two Seas Capital LP now owns 22,580,701 shares of the biotechnology company’s stock valued at $5,413,000 after buying an additional 2,051,016 shares during the last quarter. Finally, Long Focus Capital Management LLC increased its holdings in Adaptimmune Therapeutics by 15.9% in the first quarter. Long Focus Capital Management LLC now owns 23,756,687 shares of the biotechnology company’s stock valued at $4,680,000 after buying an additional 3,262,294 shares during the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.